NEONC Technology to Present at BTIG Biotech Conference | Glioblastoma Drug Neo100 in Focus | NewsOut

Biotech investors and oncology innovators — NEONC Technology (NEONC) is advancing clinical-stage therapies for aggressive brain cancers and joining the BTIG Virtual Biotechnology Conference this August. CEO Michael Reynolds will meet with institutional investors to highlight the company’s pipeline, including Neo100, a patented formulation of perillyl alcohol currently in clinical trials for glioblastoma.

As NEONC gains traction in the oncology space, its participation in BTIG signals growing interest from serious biotech stakeholders. Stay tuned as the company continues to target some of the most difficult-to-treat central nervous system cancers.

🧬 Aired on NewsOut | Hosted by Ana Berry

🏷️ Tags:
#NEONCTechnology #NEONC #GlioblastomaTreatment #Neo100 #OncologyInnovation #BTIGBiotechConference #ClinicalTrials #BiotechInvesting #BrainCancerResearch #CancerTherapies #NewsOut #AnaBerry #CNSCancers #InstitutionalInvestors #BiotechPipeline